Share Price and Basic Stock Data
Last Updated: June 23, 2025, 11:53 pm
| PEG Ratio | 0.00 |
|---|
Competitors of Sun Pharma Advanced Research Company Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Mipco Seamless Rings (Gujarat) Ltd | 9.35 Cr. | 26.1 | 37.4/26.1 | 3.60 | 0.00 % | % | % | 10.0 | |
| MPIL Corporation Ltd | 31.3 Cr. | 549 | 787/490 | 238 | 0.16 % | 12.8 % | 15.5 % | 10.0 | |
| FGP Ltd | 11.9 Cr. | 10.0 | 14.2/6.85 | 2.82 | 0.00 % | 0.00 % | 0.89 % | 10.0 | |
| Logica Infoway Ltd | 395 Cr. | 222 | 278/196 | 37.6 | 49.4 | 0.00 % | 14.0 % | 14.1 % | 10.0 |
| CRP Risk Management Ltd | 10.8 Cr. | 6.18 | 14.0/5.61 | 34.6 | 0.00 % | 0.00 % | 0.00 % | 10.0 | |
| Industry Average | 8,252.75 Cr | 256.32 | 45.90 | 105.29 | 0.04% | 48.37% | 7.43% | 9.00 |
All Competitor Stocks of Sun Pharma Advanced Research Company Ltd
Quarterly Result
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 25 | 28 | 32 | 131 | 48 | 24 | 21 | 14 | 17 | 17 | 13 | 15 | 27 |
| Expenses | 92 | 107 | 94 | 115 | 137 | 126 | 113 | 116 | 124 | 112 | 117 | 89 | 81 |
| Operating Profit | -67 | -78 | -63 | 16 | -90 | -102 | -91 | -103 | -108 | -95 | -104 | -74 | -54 |
| OPM % | -264% | -275% | -198% | 12% | -188% | -427% | -432% | -740% | -649% | -566% | -808% | -499% | -198% |
| Other Income | 0 | 0 | 0 | 0 | 11 | 10 | 8 | 6 | 4 | 2 | 0 | 0 | 0 |
| Interest | 2 | 2 | 3 | 3 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 | 5 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Profit before tax | -71 | -82 | -68 | 10 | -82 | -95 | -86 | -100 | -107 | -97 | -108 | -80 | -61 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -71 | -82 | -68 | 10 | -82 | -95 | -86 | -100 | -107 | -97 | -108 | -80 | -61 |
| EPS in Rs | -2.61 | -3.03 | -2.52 | 0.37 | -2.53 | -2.94 | -2.66 | -3.07 | -3.29 | -2.98 | -3.32 | -2.46 | -1.88 |
Last Updated: May 31, 2025, 7:39 am
Below is a detailed analysis of the quarterly data for Sun Pharma Advanced Research Company Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 27.00 Cr.. The value appears strong and on an upward trend. It has increased from 15.00 Cr. (Dec 2024) to 27.00 Cr., marking an increase of 12.00 Cr..
- For Expenses, as of Mar 2025, the value is 81.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 89.00 Cr. (Dec 2024) to 81.00 Cr., marking a decrease of 8.00 Cr..
- For Operating Profit, as of Mar 2025, the value is -54.00 Cr.. The value appears strong and on an upward trend. It has increased from -74.00 Cr. (Dec 2024) to -54.00 Cr., marking an increase of 20.00 Cr..
- For OPM %, as of Mar 2025, the value is -198.00%. The value appears strong and on an upward trend. It has increased from -499.00% (Dec 2024) to -198.00%, marking an increase of 301.00%.
- For Other Income, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00 Cr..
- For Interest, as of Mar 2025, the value is 5.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.00 Cr. (Dec 2024) to 5.00 Cr., marking an increase of 2.00 Cr..
- For Depreciation, as of Mar 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 3.00 Cr..
- For Profit before tax, as of Mar 2025, the value is -61.00 Cr.. The value appears strong and on an upward trend. It has increased from -80.00 Cr. (Dec 2024) to -61.00 Cr., marking an increase of 19.00 Cr..
- For Tax %, as of Mar 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00%.
- For Net Profit, as of Mar 2025, the value is -61.00 Cr.. The value appears strong and on an upward trend. It has increased from -80.00 Cr. (Dec 2024) to -61.00 Cr., marking an increase of 19.00 Cr..
- For EPS in Rs, as of Mar 2025, the value is -1.88. The value appears strong and on an upward trend. It has increased from -2.46 (Dec 2024) to -1.88, marking an increase of 0.58.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: June 16, 2025, 3:55 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 167 | 156 | 161 | 181 | 78 | 183 | 77 | 253 | 137 | 239 | 76 | 72 |
| Expenses | 134 | 191 | 224 | 304 | 321 | 334 | 387 | 388 | 324 | 453 | 479 | 399 |
| Operating Profit | 34 | -35 | -63 | -123 | -243 | -151 | -310 | -135 | -187 | -214 | -404 | -327 |
| OPM % | 20% | -23% | -39% | -68% | -310% | -83% | -404% | -53% | -136% | -90% | -534% | -456% |
| Other Income | 10 | 3 | 3 | 14 | 54 | 14 | 10 | 5 | 7 | 11 | 29 | 2 |
| Interest | 6 | 0 | 2 | 2 | 0 | 0 | 3 | 11 | 13 | 8 | 2 | 9 |
| Depreciation | 4 | 7 | 8 | 8 | 8 | 8 | 9 | 11 | 10 | 12 | 12 | 11 |
| Profit before tax | 34 | -40 | -70 | -119 | -197 | -145 | -312 | -151 | -203 | -223 | -388 | -345 |
| Tax % | 12% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | 30 | -40 | -70 | -119 | -197 | -145 | -312 | -151 | -203 | -223 | -388 | -345 |
| EPS in Rs | 1.23 | -1.60 | -2.83 | -4.82 | -7.85 | -5.55 | -11.92 | -5.77 | -7.48 | -6.86 | -11.96 | -10.64 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -233.33% | -75.00% | -70.00% | -65.55% | 26.40% | -115.17% | 51.60% | -34.44% | -9.85% | -73.99% | 11.08% |
| Change in YoY Net Profit Growth (%) | 0.00% | 158.33% | 5.00% | 4.45% | 91.94% | -141.57% | 166.77% | -86.04% | 24.58% | -64.14% | 85.07% |
Sun Pharma Advanced Research Company Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -7% |
| 5 Years: | -1% |
| 3 Years: | -19% |
| TTM: | -5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -2% |
| 3 Years: | -30% |
| TTM: | 11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -9% |
| 5 Years: | -1% |
| 3 Years: | -8% |
| 1 Year: | -35% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Last Updated: Unknown
Balance Sheet
Last Updated: June 16, 2025, 11:17 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 24 | 24 | 24 | 25 | 25 | 26 | 26 | 26 | 27 | 32 | 32 | 32 |
| Reserves | 116 | 76 | 8 | 133 | 160 | 270 | -45 | -194 | 4 | 480 | 92 | -253 |
| Borrowings | 5 | 4 | 56 | 3 | 2 | 2 | 67 | 236 | 79 | 16 | 56 | 265 |
| Other Liabilities | 39 | 39 | 75 | 111 | 122 | 101 | 224 | 162 | 170 | 302 | 305 | 284 |
| Total Liabilities | 184 | 143 | 163 | 273 | 309 | 398 | 273 | 230 | 280 | 830 | 486 | 329 |
| Fixed Assets | 64 | 67 | 70 | 69 | 52 | 58 | 104 | 91 | 92 | 106 | 103 | 149 |
| CWIP | 1 | 0 | 1 | 1 | 3 | 24 | 32 | 5 | 26 | 27 | 44 | 1 |
| Investments | 6 | 0 | 0 | 10 | 108 | 211 | 8 | 6 | 12 | 291 | 2 | 0 |
| Other Assets | 112 | 76 | 92 | 192 | 146 | 106 | 128 | 127 | 150 | 406 | 338 | 179 |
| Total Assets | 184 | 143 | 163 | 273 | 309 | 398 | 273 | 230 | 280 | 830 | 486 | 329 |
Below is a detailed analysis of the balance sheet data for Sun Pharma Advanced Research Company Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 32.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 32.00 Cr..
- For Reserves, as of Mar 2025, the value is -253.00 Cr.. The value appears to be declining and may need further review. It has decreased from 92.00 Cr. (Mar 2024) to -253.00 Cr., marking a decrease of 345.00 Cr..
- For Borrowings, as of Mar 2025, the value is 265.00 Cr.. The value appears to be increasing, which may not be favorable. However, Reserves are negative, which is a major warning sign. It has increased from 56.00 Cr. (Mar 2024) to 265.00 Cr., marking an increase of 209.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 284.00 Cr.. The value appears to be improving (decreasing). It has decreased from 305.00 Cr. (Mar 2024) to 284.00 Cr., marking a decrease of 21.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 329.00 Cr.. The value appears to be improving (decreasing). It has decreased from 486.00 Cr. (Mar 2024) to 329.00 Cr., marking a decrease of 157.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 149.00 Cr.. The value appears strong and on an upward trend. It has increased from 103.00 Cr. (Mar 2024) to 149.00 Cr., marking an increase of 46.00 Cr..
- For CWIP, as of Mar 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 44.00 Cr. (Mar 2024) to 1.00 Cr., marking a decrease of 43.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 2.00 Cr..
- For Other Assets, as of Mar 2025, the value is 179.00 Cr.. The value appears to be declining and may need further review. It has decreased from 338.00 Cr. (Mar 2024) to 179.00 Cr., marking a decrease of 159.00 Cr..
- For Total Assets, as of Mar 2025, the value is 329.00 Cr.. The value appears to be declining and may need further review. It has decreased from 486.00 Cr. (Mar 2024) to 329.00 Cr., marking a decrease of 157.00 Cr..
However, the Borrowings (265.00 Cr.) are higher than the Reserves (₹-253.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 29.00 | -39.00 | -119.00 | -126.00 | -245.00 | -153.00 | -377.00 | -371.00 | -266.00 | -230.00 | -460.00 | -592.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 105 | 61 | 47 | 21 | 78 | 82 | 20 | 76 | 25 | 74 | 50 | 75 |
| Inventory Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 105 | 61 | 47 | 21 | 78 | 82 | 20 | 76 | 25 | 74 | 50 | 75 |
| Working Capital Days | 72 | 129 | 21 | -42 | -59 | -232 | -98 | -557 | -96 | -97 | -189 | -509 |
| ROCE % | -20% | 21% | -32% | -71% | -94% | -143% | -62% | -183% | -242% | -218% | -67% | -109% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Small Cap Fund | 595,869 | 0.13 | 17.09 | 595,869 | 2025-04-22 17:25:19 | 0% |
| ITI Pharma and Healthcare Fund | 58,628 | 1.17 | 1.68 | 58,628 | 2025-04-22 17:25:19 | 0% |
| Nippon India Nifty Smallcap 250 Index Fund | 48,528 | 0.14 | 1.39 | 48,528 | 2025-04-22 17:25:19 | 0% |
| Motilal Oswal Nifty Smallcap 250 Index Fund | 30,326 | 0.14 | 0.87 | 30,326 | 2025-04-22 17:25:19 | 0% |
| SBI Nifty Smallcap 250 Index Fund | 23,805 | 0.14 | 0.68 | 23,805 | 2025-04-22 17:25:19 | 0% |
| ICICI Prudential Nifty Smallcap 250 Index Fund | 11,330 | 0.14 | 0.32 | 11,330 | 2025-04-22 17:25:20 | 0% |
| HDFC NIFTY Smallcap 250 ETF | 6,573 | 0.14 | 0.19 | 6,573 | 2025-04-22 17:25:20 | 0% |
| HDFC Nifty Smallcap 250 Index Fund | 5,301 | 0.14 | 0.15 | 5,301 | 2025-04-22 17:25:20 | 0% |
| Motilal Oswal Nifty 500 Index Fund | 3,060 | 0.01 | 0.09 | 3,060 | 2025-04-22 17:25:20 | 0% |
| Edelweiss Nifty Smallcap 250 Index Fund | 1,234 | 0.14 | 0.04 | 1,234 | 2025-04-22 17:25:20 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | -10.55 | -11.93 | -7.82 |
| Diluted EPS (Rs.) | -10.55 | -11.93 | -7.82 |
| Cash EPS (Rs.) | -10.17 | -11.55 | -6.50 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | -6.69 | 3.88 | 15.80 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | -6.69 | 3.88 | 15.80 |
| Revenue From Operations / Share (Rs.) | 2.21 | 2.33 | 7.36 |
| PBDIT / Share (Rs.) | -9.90 | -11.48 | -6.26 |
| PBIT / Share (Rs.) | -10.28 | -11.87 | -6.62 |
| PBT / Share (Rs.) | -10.56 | -11.92 | -6.86 |
| Net Profit / Share (Rs.) | -10.56 | -11.93 | -6.86 |
| NP After MI And SOA / Share (Rs.) | -10.56 | -11.93 | -6.86 |
| PBDIT Margin (%) | -447.74 | -493.24 | -85.09 |
| PBIT Margin (%) | -465.01 | -509.80 | -90.01 |
| PBT Margin (%) | -477.60 | -512.05 | -93.21 |
| Net Profit Margin (%) | -477.23 | -512.55 | -93.21 |
| NP After MI And SOA Margin (%) | -477.23 | -512.55 | -93.21 |
| Return on Networth / Equity (%) | 0.00 | -307.91 | -43.40 |
| Return on Capital Employeed (%) | 862.15 | -154.06 | -33.00 |
| Return On Assets (%) | -102.08 | -75.18 | -26.81 |
| Long Term Debt / Equity (X) | -0.46 | 0.00 | 0.00 |
| Total Debt / Equity (X) | -1.19 | 0.37 | 0.00 |
| Asset Turnover Ratio (%) | 0.16 | 0.11 | 0.00 |
| Current Ratio (X) | 0.06 | 1.02 | 2.54 |
| Quick Ratio (X) | 0.06 | 1.02 | 2.54 |
| Interest Coverage Ratio (X) | -35.55 | -219.89 | -26.61 |
| Interest Coverage Ratio (Post Tax) (X) | -36.89 | -227.50 | -28.15 |
| Enterprise Value (Cr.) | 5058.83 | 11897.66 | 5712.17 |
| EV / Net Operating Revenue (X) | 70.49 | 157.49 | 23.92 |
| EV / EBITDA (X) | -15.74 | -31.93 | -28.11 |
| MarketCap / Net Operating Revenue (X) | 66.92 | 158.92 | 24.39 |
| Price / BV (X) | -22.14 | 95.47 | 11.36 |
| Price / Net Operating Revenue (X) | 66.92 | 158.93 | 24.39 |
| EarningsYield | -0.07 | -0.03 | -0.03 |
After reviewing the key financial ratios for Sun Pharma Advanced Research Company Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -10.55. This value is below the healthy minimum of 5. It has increased from -11.93 (Mar 24) to -10.55, marking an increase of 1.38.
- For Diluted EPS (Rs.), as of Mar 25, the value is -10.55. This value is below the healthy minimum of 5. It has increased from -11.93 (Mar 24) to -10.55, marking an increase of 1.38.
- For Cash EPS (Rs.), as of Mar 25, the value is -10.17. This value is below the healthy minimum of 3. It has increased from -11.55 (Mar 24) to -10.17, marking an increase of 1.38.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -6.69. It has decreased from 3.88 (Mar 24) to -6.69, marking a decrease of 10.57.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -6.69. It has decreased from 3.88 (Mar 24) to -6.69, marking a decrease of 10.57.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 2.21. It has decreased from 2.33 (Mar 24) to 2.21, marking a decrease of 0.12.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -9.90. This value is below the healthy minimum of 2. It has increased from -11.48 (Mar 24) to -9.90, marking an increase of 1.58.
- For PBIT / Share (Rs.), as of Mar 25, the value is -10.28. This value is below the healthy minimum of 0. It has increased from -11.87 (Mar 24) to -10.28, marking an increase of 1.59.
- For PBT / Share (Rs.), as of Mar 25, the value is -10.56. This value is below the healthy minimum of 0. It has increased from -11.92 (Mar 24) to -10.56, marking an increase of 1.36.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -10.56. This value is below the healthy minimum of 2. It has increased from -11.93 (Mar 24) to -10.56, marking an increase of 1.37.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -10.56. This value is below the healthy minimum of 2. It has increased from -11.93 (Mar 24) to -10.56, marking an increase of 1.37.
- For PBDIT Margin (%), as of Mar 25, the value is -447.74. This value is below the healthy minimum of 10. It has increased from -493.24 (Mar 24) to -447.74, marking an increase of 45.50.
- For PBIT Margin (%), as of Mar 25, the value is -465.01. This value is below the healthy minimum of 10. It has increased from -509.80 (Mar 24) to -465.01, marking an increase of 44.79.
- For PBT Margin (%), as of Mar 25, the value is -477.60. This value is below the healthy minimum of 10. It has increased from -512.05 (Mar 24) to -477.60, marking an increase of 34.45.
- For Net Profit Margin (%), as of Mar 25, the value is -477.23. This value is below the healthy minimum of 5. It has increased from -512.55 (Mar 24) to -477.23, marking an increase of 35.32.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -477.23. This value is below the healthy minimum of 8. It has increased from -512.55 (Mar 24) to -477.23, marking an increase of 35.32.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 15. It has increased from -307.91 (Mar 24) to 0.00, marking an increase of 307.91.
- For Return on Capital Employeed (%), as of Mar 25, the value is 862.15. This value is within the healthy range. It has increased from -154.06 (Mar 24) to 862.15, marking an increase of 1,016.21.
- For Return On Assets (%), as of Mar 25, the value is -102.08. This value is below the healthy minimum of 5. It has decreased from -75.18 (Mar 24) to -102.08, marking a decrease of 26.90.
- For Long Term Debt / Equity (X), as of Mar 25, the value is -0.46. This value is below the healthy minimum of 0.2. It has decreased from 0.00 (Mar 24) to -0.46, marking a decrease of 0.46.
- For Total Debt / Equity (X), as of Mar 25, the value is -1.19. This value is within the healthy range. It has decreased from 0.37 (Mar 24) to -1.19, marking a decrease of 1.56.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.16. It has increased from 0.11 (Mar 24) to 0.16, marking an increase of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 1.5. It has decreased from 1.02 (Mar 24) to 0.06, marking a decrease of 0.96.
- For Quick Ratio (X), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 1. It has decreased from 1.02 (Mar 24) to 0.06, marking a decrease of 0.96.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -35.55. This value is below the healthy minimum of 3. It has increased from -219.89 (Mar 24) to -35.55, marking an increase of 184.34.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -36.89. This value is below the healthy minimum of 3. It has increased from -227.50 (Mar 24) to -36.89, marking an increase of 190.61.
- For Enterprise Value (Cr.), as of Mar 25, the value is 5,058.83. It has decreased from 11,897.66 (Mar 24) to 5,058.83, marking a decrease of 6,838.83.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 70.49. This value exceeds the healthy maximum of 3. It has decreased from 157.49 (Mar 24) to 70.49, marking a decrease of 87.00.
- For EV / EBITDA (X), as of Mar 25, the value is -15.74. This value is below the healthy minimum of 5. It has increased from -31.93 (Mar 24) to -15.74, marking an increase of 16.19.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 66.92. This value exceeds the healthy maximum of 3. It has decreased from 158.92 (Mar 24) to 66.92, marking a decrease of 92.00.
- For Price / BV (X), as of Mar 25, the value is -22.14. This value is below the healthy minimum of 1. It has decreased from 95.47 (Mar 24) to -22.14, marking a decrease of 117.61.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 66.92. This value exceeds the healthy maximum of 3. It has decreased from 158.93 (Mar 24) to 66.92, marking a decrease of 92.01.
- For EarningsYield, as of Mar 25, the value is -0.07. This value is below the healthy minimum of 5. It has decreased from -0.03 (Mar 24) to -0.07, marking a decrease of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Sun Pharma Advanced Research Company Ltd:
- Net Profit Margin: -477.23%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 862.15% (Industry Average ROCE: 48.37%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0% (Industry Average ROE: 7.43%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -36.89
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.06
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 45.9)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: -1.19
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -477.23%
About the Company - Qualitative Analysis
Sun Pharma Advanced Research Company Ltd. is a Public Limited Listed company incorporated on 01/03/2006 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L73100GJ2006PLC047837 and registration number is 047837. Currently Company is involved in the business activities of Research and experimental development on natural sciences and engineering. Company's Total Operating Revenue is Rs. 71.77 Cr. and Equity Capital is Rs. 32.45 Cr. for the Year ended 31/03/2025.
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Research Services | Plot No. 5 & 6/1, Savli G.I.D.C. Estate, Vadodra District Gujarat 391775 | secretarial@sparcmail.com http://www.sparc.life |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Dilip S Shanghvi | Chairman & Non-Exe.Director |
| Dr. T Rajamannar | Non Executive Director |
| Dr. Robert J Spiegel | Independent Director |
| Mr. Sudhir V Valia | Non Executive Director |
| Ms. Bhavna Doshi | Independent Director |
| Dr. Ferzaan Engineer | Independent Director |
| Ms. Vidhi Shanghvi | Non Exe.Non Ind.Director |
FAQ
What is the intrinsic value of Sun Pharma Advanced Research Company Ltd?
Sun Pharma Advanced Research Company Ltd's intrinsic value (as of 23 June 2025) is ₹12.48 — 92.05% lower the current market price of 157.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 5,092 Cr. market cap, FY2025-2026 high/low of ₹258/109, reserves of -253 Cr, and liabilities of 329 Cr.
What is the Market Cap of Sun Pharma Advanced Research Company Ltd?
The Market Cap of Sun Pharma Advanced Research Company Ltd is 5,092 Cr..
What is the current Stock Price of Sun Pharma Advanced Research Company Ltd as on 23 June 2025?
The current stock price of Sun Pharma Advanced Research Company Ltd as on 23 June 2025 is 157.
What is the High / Low of Sun Pharma Advanced Research Company Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Sun Pharma Advanced Research Company Ltd stocks is ₹258/109.
What is the Stock P/E of Sun Pharma Advanced Research Company Ltd?
The Stock P/E of Sun Pharma Advanced Research Company Ltd is .
What is the Book Value of Sun Pharma Advanced Research Company Ltd?
The Book Value of Sun Pharma Advanced Research Company Ltd is 6.80.
What is the Dividend Yield of Sun Pharma Advanced Research Company Ltd?
The Dividend Yield of Sun Pharma Advanced Research Company Ltd is 0.00 %.
What is the ROCE of Sun Pharma Advanced Research Company Ltd?
The ROCE of Sun Pharma Advanced Research Company Ltd is 298 %.
What is the ROE of Sun Pharma Advanced Research Company Ltd?
The ROE of Sun Pharma Advanced Research Company Ltd is %.
What is the Face Value of Sun Pharma Advanced Research Company Ltd?
The Face Value of Sun Pharma Advanced Research Company Ltd is 1.00.